Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
A study completed by researchers in China, of patients with renal cell carcinoma (RCC), attempted to both validate previous conclusions and look at the influencing factors of perioperative renal…
In this interview, David Polsky, MD, PhD, shares details about his advanced laboratory tumor detection technology and the study results presented at ASCO 2020. Dr. Polsky suggests that…
Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous…
In this “Practice Pearls” webinar hosted by Pharmacy Times, expert panelists discuss important topics regarding the treatment of patients with acute myeloid leukemia (AML). Panelists: Katie Culos, PharmD,…
Rajneesh Nath, MD, medical oncologist at the Banner MD Anderson Cancer Center, discusses early results from the phase 3 SIERRA trial investigating the efficacy of Iomab-B and protocol-specified…
Anna C. Pavlick, DO, director of High Reliability Organization Initiatives and co-director of the Melanoma Program at NYU Langone Health’s Perlmutter Cancer Center, overviews next generation MEK and…
Ragini Kudchadkar, MD, associate professor in the Department of Hematology and Medical Oncology, and associate director of the Hematology and Medical Oncology Fellowship Program – Clinical/Service at Emory…
In this interview, Ragini Kudchadkar, MD, associate professor in the Department of Hematology and Medical Oncology, and associate director of the Hematology and Medical Oncology Fellowship Program –…
By composing a systematic review of randomized clinical trials of patients with advanced melanoma, researchers were able to demonstrate that the risk for immune-related adverse effects (irAEs) is…
Nathan A. Pennell, MD, PhD, director of the Lung Cancer Medical Oncology Program at Taussig Cancer Institute at the Cleveland Clinic, emphasizes the importance of molecular testing before…
